Sort
10,766 grants matching “checkpoint inhibitor”
Novel therapeutics for targeting checkpoint dysfunction in cancer
$362,569Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2021 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer
$362,569Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2020 · CA
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
$362,472Neal Rosen · Sloan-Kettering Inst Can Research · P50 · FY2009 · CA
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
$362,472Ling Gao · Southern California Inst For Res/Educ · R01 · FY2024 · CA
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
$362,434David M. Ashley · Duke University · R01 · FY2024 · CA
Role of T Regulatory Cell Suppression in Autoimmunity and Cancer
$362,405Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Project 2: Targeting DNA replication in BRCA-associated breast cancer
$362,379Bing Xia · Rutgers Biomedical And Health Sciences · P01 · FY2024 · CA
Project 1: Siglec15 as a new target for lung cancer immunotherapy
$362,378Lieping Chen · Yale University · P50 · FY2021 · CA
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$362,340David E Fisher · Massachusetts General Hospital · R01 · FY2019 · CA
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
$362,294Catherine C Hedrick · La Jolla Institute For Immunology · U01 · FY2019 · CA
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating Neutrophils
$362,196Xin Lu · University Of Notre Dame · R01 · FY2025 · CA
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
$362,142David B. Solit · Sloan-Kettering Inst Can Research · P50 · FY2022 · CA
Signature-guided therapy for mismatch repair defective cancers
$362,131Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Gene Expression Signature Based Screening in Ewing Sarcoma
$362,118David J Gordon · University Of Iowa · R37 · FY2024 · CA
The Role of ZEB1 in promoting therapeutic resistance through its interaction with 53BP1Â
$362,043James M Larner · University Of Virginia · R01 · FY2023 · CA
Ciprofloxacin enhances DNA repair capacity after radiation combined injury
$361,993Juliann Gong Kiang · Henry M. Jackson Fdn For The Adv Mil/Med · R33 · FY2012 · AI
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating Neutrophils
$361,953Xin Lu · University Of Notre Dame · R01 · FY2023 · CA
Role of exosomal SPHK1 in ovarian cancer progression
$361,942Sunila Pradeep · Medical College Of Wisconsin · R01 · FY2025 · CA
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
$361,919Neal Rosen · Sloan-Kettering Inst Can Research · P50 · FY2010 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$361,866Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$361,703Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2019 · CA
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism
$361,667Roderick O'Sullivan · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA
The role of HIF2alpha in colon carcinogenesis
$361,550Yatrik M Shah · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
The role of HIF2alpha in colon carcinogenesis
$361,550Yatrik M Shah · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
The role of HIF2alpha in colon carcinogenesis
$361,550Yatrik M Shah · University Of Michigan At Ann Arbor · R01 · FY2023 · CA